This 75-minute, highly interactive symposium will feature a faculty of 2 leading experts who will address reducing ASCVD event risk with adjunctive therapies to statin use. This educational activity will provide the opportunity for the faculty and symposium participants to work through complex issues that challenge healthcare providers in caring for patients with elevated atherogenic cholesterol and triglycerides and diabetes, many of whom have been sub-optimally managed and continue to be at risk of advancing cardiovascular disease.
Enroll in this meeting
Enrollment Fee: FreeFree
Registration and Buffet Lunch
New Cholesterol Guidelines: What You Should Know
Update on Cardiovascular Outcomes Trials of Adjunctive Therapies to Statins
Omega-3 FAs and Their Use in Patients with ASCVD
Case Presentations on Primary and Secondary Prevention
At the conclusion of this activity, learners should be better able to:
- Have greater clarity on implementing the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- Describe the spectrum of major recent ASCVD randomized cardiovascular outcomes trials
- Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
- Apply evidence-based guidelines and recent randomized clinical trial evidence to lifestyle and therapeutic approaches for managing patients at high risk of cardiovascular events
The AOA Bureau of OMED is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. The AOA Bureau of OMED designates this live program activity for a maximum of 1.25 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
Supported by an independent educational grant from Amarin Pharma, Inc.